Nabin K Shrestha1, Patrick C Burke2, Amy S Nowacki3, Paul Terpeluk4, Steven M Gordon1. 1. Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA. 2. Department of Infection Prevention, Cleveland Clinic, Cleveland, Ohio, USA. 3. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USAand. 4. Department of Occupational Health, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
BACKGROUND: The aim was to evaluate the necessity of coronavirus disease 2019 (COVID-19) vaccination in persons with prior COVID-19. METHODS: Employees of the Cleveland Clinic working in Ohio on 16 December 2020, the day COVID-19 vaccination was started, were included. Anyone who tested positive for COVID-19 at least once before the study start date was considered previously infected. One was considered vaccinated 14 days after receiving the second dose of COVID-19 mRNA vaccine. Cumulative incidences of COVID-19, symptomatic COVID-19, and hospitalizations for COVID-19 were examined over the next year. RESULTS: Among 52 238 employees, 4718 (9%) were previously infected and 36 922 (71%) were vaccinated by the study's end. Cumulative incidence of COVID-19 was substantially higher throughout for those previously uninfected who remained unvaccinated than for all other groups, lower for the vaccinated than unvaccinated, and lower for those previously infected than those not. Incidence of COVID-19 increased dramatically in all groups after the Omicron variant emerged. In multivariable Cox proportional hazards regression, both prior COVID-19 and vaccination were independently associated with significantly lower risk of COVID-19. Among previously infected subjects, a lower risk of COVID-19 overall was not demonstrated, but vaccination was associated with a significantly lower risk of symptomatic COVID-19 in both pre-Omicron (HR, .60; 95% CI, .40-.90) and Omicron (HR, .36; 95% CI, .23-.57) phases. CONCLUSIONS: Both previous infection and vaccination provide substantial protection against COVID-19. Vaccination of previously infected individuals does not provide additional protection against COVID-19 for several months, but after that provides significant protection at least against symptomatic COVID-19.
BACKGROUND: The aim was to evaluate the necessity of coronavirus disease 2019 (COVID-19) vaccination in persons with prior COVID-19. METHODS: Employees of the Cleveland Clinic working in Ohio on 16 December 2020, the day COVID-19 vaccination was started, were included. Anyone who tested positive for COVID-19 at least once before the study start date was considered previously infected. One was considered vaccinated 14 days after receiving the second dose of COVID-19 mRNA vaccine. Cumulative incidences of COVID-19, symptomatic COVID-19, and hospitalizations for COVID-19 were examined over the next year. RESULTS: Among 52 238 employees, 4718 (9%) were previously infected and 36 922 (71%) were vaccinated by the study's end. Cumulative incidence of COVID-19 was substantially higher throughout for those previously uninfected who remained unvaccinated than for all other groups, lower for the vaccinated than unvaccinated, and lower for those previously infected than those not. Incidence of COVID-19 increased dramatically in all groups after the Omicron variant emerged. In multivariable Cox proportional hazards regression, both prior COVID-19 and vaccination were independently associated with significantly lower risk of COVID-19. Among previously infected subjects, a lower risk of COVID-19 overall was not demonstrated, but vaccination was associated with a significantly lower risk of symptomatic COVID-19 in both pre-Omicron (HR, .60; 95% CI, .40-.90) and Omicron (HR, .36; 95% CI, .23-.57) phases. CONCLUSIONS: Both previous infection and vaccination provide substantial protection against COVID-19. Vaccination of previously infected individuals does not provide additional protection against COVID-19 for several months, but after that provides significant protection at least against symptomatic COVID-19.
Authors: Maria Elena Flacco; Graziella Soldato; Cecilia Acuti Martellucci; Giuseppe Di Martino; Roberto Carota; Antonio Caponetti; Lamberto Manzoli Journal: Front Public Health Date: 2022-05-02
Authors: Jan Martínek; Hana Tomášková; Jaroslav Janošek; Hana Zelená; Alena Kloudová; Jakub Mrázek; Eduard Ježo; Vlastimil Král; Jitka Pohořská; Hana Šturcová; Rastislav Maďar Journal: Viruses Date: 2022-05-18 Impact factor: 5.818
Authors: Efrén Murillo-Zamora; Xóchitl Trujillo; Miguel Huerta; Mónica Ríos-Silva; José Guzmán-Esquivel; Verónica Benites-Godínez; María Regina Ochoa-Castro; José Alejandro Guzmán-Solórzano; Oliver Mendoza-Cano Journal: Int J Infect Dis Date: 2022-04-25 Impact factor: 12.074
Authors: Susan L Uprichard; Amornrat O'Brien; Monika Evdokimova; Cynthia L Rowe; Cara Joyce; Matthew Hackbart; Yazmin E Cruz-Pulido; Courtney A Cohen; Michelle L Rock; John M Dye; Paul Kuehnert; Keersten M Ricks; Marybeth Casper; Lori Linhart; Katrina Anderson; Laura Kirk; Jack A Maggiore; Andrew S Herbert; Nina M Clark; Gail E Reid; Susan C Baker Journal: Viruses Date: 2022-02-10 Impact factor: 5.048